- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Michael Cohen Contrasts the Manifestation and Treatment of Wet vs Dry AMD
Michael N. Cohen, MD, a retinal surgeon at Wills Eye Hospital and Mid Atlantic Retina, describes the differences between wet and dry age-related macular degeneration (AMD) and how gene therapy could help treat the condition in the future.
Transcript
How does geographic atrophy differ from other forms of age-related macular degeneration and how can gene therapy address it?
Cohen: So, macular degeneration comes in 2 types: dry and wet. We have excellent treatment for the wet form of the disease, which is when blood vessels grow underneath the retina.
The dry form of the disease is a little different. Early on, this is marked by several findings we see in the retina, that buildup called drusen. As things progress over time, it can lead to atrophy or loss of cells at the outer retina, which can be pretty visually devastating.
Right now, we have no treatment in terms of really effectively dealing with it. The route of administration of a lot of our medications is injections into the vitreous cavity. And so, there are always potential risks involved with this, even though they're quite small. But it is a burden some issue to patients in terms of needing quite a high number of injections to control their disease right now and that's what we see in the wet form of macular degeneration. The hope of gene therapy is that even though the route of administration is the same injection into the vitreous cavity, it has the potential for a much, much longer lasting effect, which would really limit that injection burden.
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
HS Treatment Goals: Better Quality of Life, Not Just Control
January 3rd 2025For part 3 of our discussion with Chris Sayed, MD, we tackle several important topics in the hidradenitis suppurative (HS) and inflammatory disease space: patient quality of life, medication and treatment goals, and the possibility of a cure.
Read More
Dr Yehuda Handelsman: DCRM Guidelines Are Shaping Integrated, Global CRM Care
January 3rd 2025In part 2 of our interview, Yehuda Handelsman, MD, discusses how cardiorenalmetabolic (CRM) disease management is advancing with the 2022 Diabetes, Cardiorenal, and Metabolic (DCRM) multispecialty practice recommendations and the updated DCRM 2.0 guidelines.
Read More
Stripped of Fucose, Powerful Monoclonal Antibody Shows Promising Results in MDS Dosing Study
January 2nd 2025Nicole Grieselhuber, MD, PhD, of The Ohio State University, discusses results from Part D of a dosing study involving patients with previously untreated higher-risk myelodysplastic syndrome (MDS) who were treated with a combination of SEA-CD70 and azacitidine.
Read More
